Dr. Paul Goodyer, a Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, will be the principal investigator in the Phase 2 clinical trial Genome Quebec and Genome Canada provides non-dilutive funding for the Phase 2 clinical...
Immunicom, Inc., a medical technology company awarded FDA Breakthrough Device Designation for Immunopheresis™, its non-pharmaceutical solution for treating stage IV metastatic cancer, began treating its first of 170 triple-negative breast cancer (TNBC) patients...
HIGH POINT, N.C.–(BUSINESS WIRE)–vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing the liver-selective glucokinase activator TTP399 in adult patients with...
Highlights First patient received first dose in INSIGHT-004, a phase I clinical trial Evaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer indications Patient recruitment for the trial is ongoing in Germany, with first data...
Canopy Growth Corporation’s (NYSE:CGC) medical division Spectrum Therapeutics has shared an update on the progress of its development and commercialization of validated cannabis medicines through clinical trials. There is an increasing demand for cannabinoid-based...
SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, announced the first patient has been enrolled in Part 2 of JX594-REN026, a Phase 1b clinical trial of Pexa-Vec...
Email
Text